

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE – STRATEGIC COOPERATION
FRAMEWORK AGREEMENT

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company on the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company entered into a strategic cooperation framework agreement (the “**Strategic Cooperation Framework Agreement**”) with Tianjin Ringpu Bio-Technology Co., Ltd. (“**Tianjin Ringpu**”) on June 26, 2023.

Pursuant to the Strategic Cooperation Framework Agreement, the Company and Tianjin Ringpu will jointly develop monoclonal antibody drugs and genetically engineered vaccines for pets (“**Potential Pipeline Products**”). The Company will provide R&D support to Tianjin Ringpu using its technical advantages in the human monoclonal antibody, protein and genetically engineered vaccine and other fields. The Company will be responsible for the basic R&D and verification of products, while Tianjin Ringpu will be responsible for facilitating the process of clinical trials, registration, production and commercialization of the Potential Pipeline Products. The Company agreed Tianjin Ringpu to be its sole partner with respect to the development, registration, production and sales for the Potential Pipeline Products.

The Directors are of the view that, riding on Tianjin Ringpu’s experience in animal experiments, animal husbandry, veterinary science and technology and other aspects, the technical expertise of the Company in recombinant protein, monoclonal antibody and other fields could be further enhanced, and hence such arrangements as stipulated in the Strategic Cooperation Framework Agreement are in line with the Company’s long-term development strategy and the interests of all shareholders of the Company.

ABOUT TIANJIN RINGPU

Tianjin Ringpu is a company listed on the Shenzhen Stock Exchange (stock code: 300119) and is principally engaged in the development and production of medicinal plant preparations, chemical pharmaceutical preparations and biological pharmaceutical preparations for animal disease treatment, prevention, diagnosis, growth promotion, immune regulation, etc.. As of the date of this announcement, Tianjin Ringpu holds approximately 35.00% interests of Tianjin Huapu Haihe Biopharmaceutical Industry Fund Partnership (Limited Partnership) (天津華普海河生物醫藥產業基金合夥企業(有限合夥)) (“**Huapu Haihe**”), and Huapu Haihe holds approximately 99.9% interests of Tianjin Huapu Biopharmaceutical Technology Partnership (Limited Partnership) (天津華普生物醫藥科技合夥企業(有限合夥)) (“**Tianjin Huapu**”), which is one of the shareholders of the Company (holding 3,043,478 H Shares, representing approximately 1.50% of the total issued share capital of the Company as of the date of this announcement).

ABOUT THE COMPANY

The Company is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its inception in 2001, the Company has focused on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers the Company to develop its recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability.

The Board wishes to emphasize that the cooperation contemplated under the Strategic Cooperation Framework Agreement is subject to the entering into of formal agreements between the parties. Accordingly, any further business development described above may or may not materialize. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the Company’s shares.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, June 26, 2023

As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshe and Ms. HOU Aijun as independent non-executive Directors.